In-vitro Toxicology Assays Industry

The global in-vitro toxicology testing market size was estimated at USD 31.03 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 11.17% from 2024 to 2030. The growth of the market is attributed to continuous developments in toxicology research and advancement of technologies. In addition, rising emphasis on development of personalized medicines is further expected to boost the market during the forecast period. Awareness regarding the limitations and challenges associated with traditional toxicology screening methods has been growing. This has led to a broader acceptance of in-vitro testing as a valuable tool for assessing the safety and efficacy of compounds.

In recent times, validation, and acceptance of in vitro and alternative testing methods by regulatory authorities is increasing at a lucrative rate. In addition, ongoing technological advancements to replace the use of animals for toxicology testing purposes have increased the use of in vitro screening and monitoring models. The advent of 3D cell culture is recognized as one of the most significant advancements, which enables safety testing of new compounds in the in vitro environment that mirrors the host physiology. As a result, researchers are engaged in developing and adapting novel in vitro test methods based on 3D human tissue constructs, co-culture systems, and kinetic tissue culture methods to address the various issues related to animal testing. Various examples of nonanimal technologies that are developed against animal testing are direct peptide reactivity assay, ARE-Nrf2 Luciferase assay, and Human Cell Line Activation Test (h-CLAT). Furthermore, the development of an integrated approach is recognized as a key to capitalizing on market opportunities. Another development that is anticipated to greatly influence the growth of this market is the growing trend of outsourcing toxicology assessment services.

Gather more insights about the market drivers, restrains and growth of the Global In-vitro Toxicology Assays market

The usage of new food additives along with innovations in food contact substance development has propelled manufacturers and researchers to explore the use of high-throughput chemical toxicity testing. Moreover, limited resources with respect to budget and time for examining chemicals have fomented the product manufacturers to adopt new cost-effective methods for animal-free (in vitro) High-Throughput Screening (HTS). One such method is the quantitative HTS (qHTS) program, which is considered a cost- and time-efficient method for toxicological evaluation. Furthermore, ongoing development in these programs is anticipated to expand the application scope of in vitro testing market. For example, the development of Collaborative Programs Tox21, a multi-agency, automated qHTS program, for efficient safety testing of chemicals by enhancing efficiency along with reduction of overall testing costs. However, such a program exhibits certain challenges such as extrapolation of such data to decide in vivo doses. Moreover, the data required to implement the use of information acquired from in vitro testing assay to estimate and validate the dosage of a drug product in the target organ or disease site are often unavailable.

Furthermore, several academic centers have taken in vitro toxicology initiatives to expand on the use of in vitro models across various applications, such as skin toxicity and genotoxicity. Development and implementation of suitable in vitro models that deliver highly relevant biological data across several therapeutic areas are aiding segment growth; for example, the use of Reinnervate’s Alvetex, a synthetic scaffold, to design 3D culture assays for routine assessment of cancer cell cytotoxicity. Moreover, a group of researchers from the University of CESPU Health Sciences Department, Portugal, and Albert Labs International Corp. announced a collaboration to conduct toxicology testing on KRN-101, a candidate for mental health.

Key Companies & Market Share Insights

Some of the key players operating in the market include Charles River Laboratories International, Inc., SGS S.A., Merck KGaA, Eurofins Scientific, and Abbott Laboratories. These companies focus on expanding their service portfolios, enhancing technological capabilities, and strategic collaborations to strengthen their market presence. With increasing demand for reliable and cost-effective testing solutions, these companies are actively engaged in innovative research and development to address emerging challenges in toxicology testing.

Emerging players in the in-vitro toxicology testing market, like InSphero and MatTek Corporation, are leveraging cutting-edge technologies and forming strategic partnerships to gain a foothold. Their activities include developing advanced 3D cell culture models and organ-on-a-chip platforms. These companies aim to disrupt the market by offering innovative and more predictive in-vitro toxicology solutions, catering to the growing demand for alternatives to traditional animal testing methods.

Key In-vitro Toxicology Testing Companies:

• Charles River Laboratories International, Inc.
• SGS S.A.
• Merck KGaA
• Eurofins Scientific
• Abbott Laboratories
• Laboratory Corporation of America Holdings
• Evotec S.E.
• Thermo Fisher Scientific, Inc.
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.
• Catalent, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• BioIVT
• Gentronix

Recent Developments

• In April 2023, Thermo Fisher Scientific launched its first real-time PCR assay kit 37 CE-IVD for testing of infectious diseases.
• In April 2023, Gentronix, Ltd expanded its laboratory with the aim of fulfilling the growing demand.
• In February 2023, Evotec announced the relocation of Cyprotex US, LLC—a subsidiary of Evotec—from Watertown to Framingham, U.S. This relocation had the motto of expanding the new facility for faster turnaround time.
• In March 2022, WuXi AppTec expanded its toxicology footprint abilities with new a Chengdu facility. This expansion helped them ensure better service with faster initiation for clinical studies.
• In January 2021, Charles River announced a partnership with Cypre, Inc. to expand its 3D in vitro services for cancer immunotherapy as well as targeted therapy drug screening. This partnership enabled the company to access Cypre’s patented 3D hydrogel patterning technology, or Falcon-X, to expand its in vitro testing services.

Order a free sample PDF of the In-vitro Toxicology Assays Market Intelligence Study, published by Grand View Research.